| Ytd | -3.90% | |
| 1y | 23.68% |
| Open | 26.92 | Prev Close | 27.29 | Low | 26.47 | High | 27.17 | Mkt Cap | 3.19B |
| Vol | 1.54M | Avg Vol | 2.63M | EPS | -3.11 | P/E | -48.44 | Forward P/E | -6.91 |
| Beta | 2.18 | Short Ratio | 9.65 | Inst. Own | 106.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 31.35 | 200-d Avg | 28.11 | 1yr Est | 51.36 |
BEAM News
Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ: BEAM) by 1
Beam Therapeutics' growing pipeline could reward patient investors.
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing cont
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dis
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its A
B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy an
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destr
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) wi
Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-target
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Maj
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runw
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Tran
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including
Beam Therapeutics develops precision genetic medicines using base editing technology to target serio
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C.,
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and p
Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine compa
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechn
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechn
Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil
On Tuesday, 647 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
Gainers